Dawn C. Buse (Bronx, NY/ US), Elizabeth Leroux (Montreal/ CA), Michel Lanteri-Minet (Nice/ FR), Fumihiko Sakai (Chuo-ku, Saitama City/ JP), Manjit Matharu (London/ GB), Zaza Katsarava (Unna/ DE), Michael Reed (Chapel Hill, NC/ US), Kristina Fanning (Wilmington, NC/ US), Aubrey Manack Adams (Irvine, CA/ US), Katherine Sommer (Irvine, CA/ US), Richard B. Lipton (Bronx, NY/ US)
Abstract text (incl. figure legends and references)
Objective: To describe the methodology and present findings on migraine diagnosis, consulting, and current medication use for migraine across 6 countries.
Methods: CaMEO-I was a cross-sectional, observational, web-based study in 2021 in 6 countries: US, Canada, UK, Germany, France, and Japan. A validated questionnaire identified patients with migraine based on modified International Classification of Headache Disorders, 3rd ed (mICHD-3) criteria. Qualified respondents provided sociodemographic background, headache features, migraine disability based on the Migraine Disability Assessment Scale (MIDAS), and history of consulting, diagnosis, and treatment patterns.
Results: A total of 14,492 individuals met criteria for migraine (approximately 2400 from each country) and were included in this analysis. The mean age among migraine respondents ranged from 40.3-42.3 years and the majority were female (68.7-73.8%). Median monthly headache days (MHDs) ranged from 2.3 to 3.3 days, with between 5.4% (France) to 9.5% (Japan) of respondents reporting ≥15 MHDs. Moderate-to-severe migraine-related disability was reported between 30.3% (Japan) to 52.0% (Germany) of migraine respondents (Figure). Self-reported medical diagnosis (SRMD) rates for migraine, chronic/transformed migraine, or menstrual migraine among those meeting the ICHD-3 case definition ranged from 42.8% (Japan) to 49.3% (US). The SRMD rates for chronic/transformed migraine ranged from 0.7% (Japan) to 4.8% (US) of respondents with migraine. In the overall migraine population, rates of current preventive use ranged from 6.4% (Japan) to 16.8% (US).
Conclusions: Between one-third and one-half of respondents who met mICHD-3 criteria for migraine reported moderate to severe migraine-related disability as measured by MIDAS. While there were between-country differences in the proportion of CaMEO-I respondents with an SRMD of migraine and chronic migraine, underdiagnosis of migraine was a concern in each country studied.
We use cookies on our website. Cookies are small (text) files that are created and stored on your device (e.g., smartphone, notebook, tablet, PC). Some of these cookies are technically necessary to operate the website, other cookies are used to extend the functionality of the website or for marketing purposes. Apart from the technically necessary cookies, you are free to allow or not allow cookies when visiting our website.